Please upgrade your browser.
Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer
Nephron-sparing surgery (NSS) remains gold standard for the treatment of localised renal cell cancer (RCC), even in the case of a normal contralateral kidney.
Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study
Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.
Comparative study of renal cell carcinoma in patients less than 40 years of age and older age patients: A retrospective single-center study
Renal cell carcinoma (RCC) is typically found in the older age group between 50 and 70 years of age. However, diagnosis of renal cancer is increasing more rapidly in patients less than 40 years if age compared to older age patients.
This article explains how to support a loved one after cancer treatment.
Kidney cancer had the sharpest annual increase for young Americans: 6.23% between 1995 and 2014.
Gretchen Vaughan, Kidney Cancer Association, has been named chief executive officer of the nonprofit.
According to a study that was published in Urologic Oncology, patients with metastatic non-clear-cell renal cell carcinoma (nccRCC) have worse outcomes from first-line therapy with tyrosine kinase inhibitors (TKIs) than patients with metastatic clear-cell RCC (ccRCC).
Researchers at the Dana-Farber Cancer Institute are working to develop a vaccine for the treatment of renal cell cancer.
Personalised treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published in the journal Radiology.
Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
This study evaluates whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).
|Powered by NeonCRM|